Short Interest in Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Grows By 36.8%

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) saw a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 53,900 shares, an increase of 36.8% from the February 13th total of 39,400 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 539.0 days. Approximately 0.0% of the company’s shares are short sold.

Inhibitor Therapeutics Price Performance

INTI stock remained flat at $0.07 during midday trading on Tuesday. Inhibitor Therapeutics has a twelve month low of $0.04 and a twelve month high of $0.14. The firm has a market capitalization of $12.06 million, a PE ratio of -7.00 and a beta of -0.55. The stock’s 50 day simple moving average is $0.06 and its 200-day simple moving average is $0.07.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.